Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
about
Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative mediumPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsIn vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolatesEfficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosisAntifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileAntifungal and immunomodulating activities of 1,4-benzothiazine azole derivatives: review.Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasisFluconazole versus Candida albicans: a complex relationship.Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates.Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasisAntifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.A new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cellsIn vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisClinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis modelEmerging Issues in Nosocomial Fungal Infections.Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout miceIn vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Antifungal agents: chemotherapeutic targets and immunologic strategies.In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesOral candidal infections and antimycotics.Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species.Resistance of Candida species to fluconazoleSCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.Detection of amphotericin B-resistant Candida isolates in a broth-based system.Use of amphotericin B with azole antifungal drugs: what are we doing?Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolatesComparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative studyTreatment of murine Candida krusei or Candida glabrata infection with L-743,872Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic miceContribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit.Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.Antifungals: need to search for a new molecular target
P2860
Q24630977-92A1E570-02BD-4163-89B2-37D5329647B4Q27025299-EFBDE4E0-2ED8-49E7-AC6F-0B515EA6A5AAQ28378977-BFA0E7BC-C7A9-4C20-9056-3C1849B7D972Q28379470-0A8ABC98-194B-4249-9B23-D729AE26E64EQ28489096-3421A4C5-0273-454D-9413-3FE9B5692B45Q32100806-B857F1B2-47CB-4733-A6D9-8D49E4FF2F1FQ33689568-D9BA0C84-99B9-4AB1-9532-D7C90E9F334DQ33690616-10FF92CD-BA4C-4D17-BE13-833FD498CAE1Q33701518-C1521BE9-CBDF-4BC3-804D-079F4BF7709DQ33714825-E5A248EB-B8C3-4FE1-83EC-DCC2AB484487Q33967543-433F211D-881E-4C83-A567-69E1C29B07EDQ33972828-1EB1C693-7F5D-4567-A116-8AE53B3A32F7Q33977551-E8F89EBE-9D52-43F2-BF60-294892C257AAQ33977602-AB4192DF-E027-475C-A545-604DC43032C5Q33979115-8E0CA733-9B46-47C3-A60C-B9775221952FQ33980195-492889A3-49C1-4117-8AA4-2B06A2560558Q33980421-17C65C29-7511-4307-A179-0DB9B29F089FQ33980741-43CF226B-810E-4225-AFDB-9B6C9F65A9CEQ33981712-573C7B92-0C09-4D0E-8B66-3D2C99E251C4Q34092228-54F9EAA6-33FF-44A7-82A8-56A50AF2267FQ34107525-8BC5C697-BE07-44BC-B063-E71D044B8C49Q34142406-3203D294-543C-4CF8-A765-D50D1B9B4CBEQ34335230-78386083-BB71-402B-AEE6-A7017BC35955Q34400044-F5A4FE2C-6493-4F23-935D-BCE01C9A30EEQ34452652-B78B310F-B032-48E5-BDFE-D66F9A49FE9EQ34632651-B643769C-787A-47A0-AE25-75890D6A8A90Q34774346-CC5E4C1D-F765-4B74-8A2D-0DBCDE7995CBQ35110522-FBB1C6AF-6368-4BED-AE76-A2CF7A430BD6Q35112747-B86B6C37-9016-4BB4-B44C-577526E207F8Q35113517-D22C4663-306E-4DA5-8244-B7B03D29B83AQ35117932-FB628A84-E499-4438-ACA0-8256DA6B1DF8Q35120311-C6B09718-22E2-4474-AEEA-8DDF7AC45A65Q35124771-F6CC8532-1FFB-4C87-88C5-9A459CFA0D46Q35128351-5BC9815A-4C1C-41F2-8185-4D914B186549Q35138062-C6FF0A81-E5ED-4182-9938-AA80AEEEB78FQ35822610-56AE13B4-E08B-4B03-83A5-53184D8F3C65Q36526696-BBFA139A-39F8-4153-9752-D2734F0B5B9CQ36528018-E54672E5-468A-40F9-9AE2-D2976043DF52Q36542830-5FC9BA45-500F-4355-B4D7-6CC6E9E57639Q37666705-8473B781-C6A7-45F7-B67D-9DCCEA696781
P2860
Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Correlation between in vitro a ...... gents against Candida species.
@en
Correlation between in vitro a ...... gents against Candida species.
@nl
type
label
Correlation between in vitro a ...... gents against Candida species.
@en
Correlation between in vitro a ...... gents against Candida species.
@nl
prefLabel
Correlation between in vitro a ...... gents against Candida species.
@en
Correlation between in vitro a ...... gents against Candida species.
@nl
P2093
P356
P1476
Correlation between in vitro a ...... gents against Candida species.
@en
P2093
Anaissie EJ
Dignani MC
Karyotakis NC
Paetznick V
P304
P356
10.1093/INFDIS/170.2.384
P407
P577
1994-08-01T00:00:00Z